Global Medications for Alcohol Use Disorder (AUD) 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI10250773

Publication Date:

October 15, 2024

Pages:

101

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Alcohol use disorder (AUD), is a chronic condition characterized by an inability to control alcohol consumption despite negative consequences. It involves a physical and psychological dependence on alcohol, where individuals may experience cravings, withdrawal symptoms, and a persistent desire to drink. Medications for Alcohol Use Disorder (AUD) are an important component of treatment, helping individuals manage cravings, reduce alcohol consumption, and maintain sobriety. Currently, commonly used drugs include naltrexone, acamprosate, etc.
The global Medications for Alcohol Use Disorder (AUD) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (publisher)' newest research report, the 鈥淢edications for Alcohol Use Disorder (AUD) Industry Forecast鈥� looks at past sales and reviews total world Medications for Alcohol Use Disorder (AUD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Medications for Alcohol Use Disorder (AUD) sales for 2023 through 2029. With Medications for Alcohol Use Disorder (AUD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medications for Alcohol Use Disorder (AUD) industry.
This Insight Report provides a comprehensive analysis of the global Medications for Alcohol Use Disorder (AUD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Medications for Alcohol Use Disorder (AUD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Medications for Alcohol Use Disorder (AUD) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medications for Alcohol Use Disorder (AUD) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medications for Alcohol Use Disorder (AUD).
United States market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Medications for Alcohol Use Disorder (AUD) players cover Alkermes, Merck KGaA, Lundbeck, Alvogen, Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Medications for Alcohol Use Disorder (AUD) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Naltrexone
Acamprosate
Disulfiram
Other
Segmentation by Application:
Hospital
Rehabilitation Institutions
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Naltrexone
Acamprosate
Disulfiram
Other
Segmentation by Application:
Hospital
Rehabilitation Institutions
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alkermes
Merck KGaA
Lundbeck
Alvogen
Mylan
Teva
Sun Pharmaceutical Industries
Zydus Pharmaceuticals
Taj Pharmaceuticals
TAGI Pharma Inc.
Beijing Wellso Pharmaceutical Co
Glenmark Pharmaceuticals
Rusan Pharma Ltd

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size 2019-2030
2.1.2 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Medications for Alcohol Use Disorder (AUD) by Country/Region, 2019, 2023 & 2030
2.2 Medications for Alcohol Use Disorder (AUD) Segment by Type
2.2.1 Naltrexone
2.2.2 Acamprosate
2.2.3 Disulfiram
2.2.4 Other
2.3 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Type
2.3.1 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Medications for Alcohol Use Disorder (AUD) Segment by Application
2.4.1 Hospital
2.4.2 Rehabilitation Institutions
2.4.3 Others
2.5 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Application
2.5.1 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Player
3.1 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Medications for Alcohol Use Disorder (AUD) Revenue by Player (2019-2024)
3.1.2 Global Medications for Alcohol Use Disorder (AUD) Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Medications for Alcohol Use Disorder (AUD) Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Medications for Alcohol Use Disorder (AUD) by Region
4.1 Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Region (2019-2024)
4.2 Global Medications for Alcohol Use Disorder (AUD) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size Growth (2019-2024)
4.4 APAC Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size Growth (2019-2024)
4.5 Europe Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Country (2019-2024)
5.2 Americas Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Type (2019-2024)
5.3 Americas Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Region (2019-2024)
6.2 APAC Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Type (2019-2024)
6.3 APAC Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Country (2019-2024)
7.2 Europe Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Type (2019-2024)
7.3 Europe Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Medications for Alcohol Use Disorder (AUD) by Region (2019-2024)
8.2 Middle East & Africa Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Medications for Alcohol Use Disorder (AUD) 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Medications for Alcohol Use Disorder (AUD) 麻豆原创 Forecast
10.1 Global Medications for Alcohol Use Disorder (AUD) Forecast by Region (2025-2030)
10.1.1 Global Medications for Alcohol Use Disorder (AUD) Forecast by Region (2025-2030)
10.1.2 Americas Medications for Alcohol Use Disorder (AUD) Forecast
10.1.3 APAC Medications for Alcohol Use Disorder (AUD) Forecast
10.1.4 Europe Medications for Alcohol Use Disorder (AUD) Forecast
10.1.5 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Forecast
10.2 Americas Medications for Alcohol Use Disorder (AUD) Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.2.2 Canada 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.2.3 Mexico 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.2.4 Brazil 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.3 APAC Medications for Alcohol Use Disorder (AUD) Forecast by Region (2025-2030)
10.3.1 China Medications for Alcohol Use Disorder (AUD) 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.3.3 Korea 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.3.4 Southeast Asia 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.3.5 India 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.3.6 Australia 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.4 Europe Medications for Alcohol Use Disorder (AUD) Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.4.2 France 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.4.3 UK 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.4.4 Italy 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.4.5 Russia 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.5 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.5.2 South Africa 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.5.3 Israel 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.5.4 Turkey 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
10.6 Global Medications for Alcohol Use Disorder (AUD) Forecast by Type (2025-2030)
10.7 Global Medications for Alcohol Use Disorder (AUD) Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Medications for Alcohol Use Disorder (AUD) Forecast
11 Key Players Analysis
11.1 Alkermes
11.1.1 Alkermes Company Information
11.1.2 Alkermes Medications for Alcohol Use Disorder (AUD) Product Offered
11.1.3 Alkermes Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Alkermes Main Business Overview
11.1.5 Alkermes Latest Developments
11.2 Merck KGaA
11.2.1 Merck KGaA Company Information
11.2.2 Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Offered
11.2.3 Merck KGaA Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Merck KGaA Main Business Overview
11.2.5 Merck KGaA Latest Developments
11.3 Lundbeck
11.3.1 Lundbeck Company Information
11.3.2 Lundbeck Medications for Alcohol Use Disorder (AUD) Product Offered
11.3.3 Lundbeck Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Lundbeck Main Business Overview
11.3.5 Lundbeck Latest Developments
11.4 Alvogen
11.4.1 Alvogen Company Information
11.4.2 Alvogen Medications for Alcohol Use Disorder (AUD) Product Offered
11.4.3 Alvogen Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Alvogen Main Business Overview
11.4.5 Alvogen Latest Developments
11.5 Mylan
11.5.1 Mylan Company Information
11.5.2 Mylan Medications for Alcohol Use Disorder (AUD) Product Offered
11.5.3 Mylan Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Mylan Main Business Overview
11.5.5 Mylan Latest Developments
11.6 Teva
11.6.1 Teva Company Information
11.6.2 Teva Medications for Alcohol Use Disorder (AUD) Product Offered
11.6.3 Teva Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Teva Main Business Overview
11.6.5 Teva Latest Developments
11.7 Sun Pharmaceutical Industries
11.7.1 Sun Pharmaceutical Industries Company Information
11.7.2 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Offered
11.7.3 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Sun Pharmaceutical Industries Main Business Overview
11.7.5 Sun Pharmaceutical Industries Latest Developments
11.8 Zydus Pharmaceuticals
11.8.1 Zydus Pharmaceuticals Company Information
11.8.2 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Offered
11.8.3 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Zydus Pharmaceuticals Main Business Overview
11.8.5 Zydus Pharmaceuticals Latest Developments
11.9 Taj Pharmaceuticals
11.9.1 Taj Pharmaceuticals Company Information
11.9.2 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Offered
11.9.3 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Taj Pharmaceuticals Main Business Overview
11.9.5 Taj Pharmaceuticals Latest Developments
11.10 TAGI Pharma Inc.
11.10.1 TAGI Pharma Inc. Company Information
11.10.2 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Offered
11.10.3 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 TAGI Pharma Inc. Main Business Overview
11.10.5 TAGI Pharma Inc. Latest Developments
11.11 Beijing Wellso Pharmaceutical Co
11.11.1 Beijing Wellso Pharmaceutical Co Company Information
11.11.2 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Offered
11.11.3 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Beijing Wellso Pharmaceutical Co Main Business Overview
11.11.5 Beijing Wellso Pharmaceutical Co Latest Developments
11.12 Glenmark Pharmaceuticals
11.12.1 Glenmark Pharmaceuticals Company Information
11.12.2 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Offered
11.12.3 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Glenmark Pharmaceuticals Main Business Overview
11.12.5 Glenmark Pharmaceuticals Latest Developments
11.13 Rusan Pharma Ltd
11.13.1 Rusan Pharma Ltd Company Information
11.13.2 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Offered
11.13.3 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Rusan Pharma Ltd Main Business Overview
11.13.5 Rusan Pharma Ltd Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.